Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African American Patients with Type 2 Diabetes? A Meta-analysis

被引：0
|
作者：
Mishriky, Basem M.
Powell, James R.
Wittwer, Jennifer A.
Chu, Jennifer X.
Sewell, Kerry
Wu, Qiang
Cummings, Doyle M.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-242-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
    Limonte, Christine P.
    Hall, Yoshio N.
    Trikudanathan, Subbulaxmi
    Tuttle, Katherine R.
    Hirsch, Irl B.
    de Boer, Ian H.
    Zelnick, Leila R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (06)
  • [32] Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
    Clemmensen, K. K. B.
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S29 - S29
  • [33] Prevalence of SGLT2i and GLP1RA Use among US Adults with Type 2 Diabetes
    Limonte, Christine
    Hall, Yoshio
    Trikudanathan, Subbulaxmi
    Tuttle, Katherine R.
    Hirsch, Irl B.
    De Boer, Ian
    Zelnick, Leila
    DIABETES, 2022, 71
  • [34] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [35] Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
    Li, Xuefeng
    Wu, Hongli
    Peng, Huifang
    Jiang, Hongwei
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [36] Patient, provider and formulary characteristics associated with initiation of a SGLT2i or GLP-1RA among medicare beneficiaries with type 2 diabetes: A retrospective cohort study
    Luo, Jing
    Hernandez, Inmaculada
    Gabriel, Joseph
    Gellad, Walid
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 307 - 308
  • [37] Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
    Lisco, Giuseppe
    De Tullio, Anna
    Disoteo, Olga
    De Geronimo, Vincenzo
    Piazzolla, Giuseppina
    De Pergola, Giovanni
    Giagulli, Vito Angelo
    Jirillo, Emilio
    Guastamacchia, Edoardo
    Sabba, Carlo
    Triggiani, Vincenzo
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [38] Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
    King, Aaron
    Tan, Xi
    Dhopeshwarkar, Neil
    Bohn, Rhonda
    Dea, Katherine
    Leonard, Charles E.
    de Havenon, Adam
    BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (05)
  • [39] Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus
    Jensen, Simon Kok
    Heide-Jorgensen, Uffe
    Andersen, Ina Trolle
    Thomsen, Reimar
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I197 - I198
  • [40] Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus
    Jensen, Simon Kok
    Heide-Jorgensen, Uffe
    Andersen, Ina Trolle
    Thomsen, Reimar
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
12345